Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 159

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

A Pilot Trial of the Alpha‐1 Adrenergic Antagonist, Prazosin, for Alcohol Dependence

Open access
Simpson, Tracy L., Saxon, Andrew J., Meredith, Charles W., Malte, Carol A., McBride, Brittney, Ferguson, Laura C., Gross, Christopher A., Hart, Kim L., Raskind, Murray · 2009 · Alcoholism: Clinical and Experimental Research

Abstract

Background: Current medications for alcohol dependence (AD) show only modest efficacy. None target brain noradrenergic pathways. Theory and preclinical evidence suggest that noradrenergic circuits may be involved in alcohol reinforcement and relapse. We therefore tested the α‐1 adrenergic receptor antagonist, prazosin, as a pharmacotherapy for AD. Methods: We randomized 24 participants with AD but without posttraumatic stress disorder to receive either prazosin or placebo in a 6‐week, double‐blind pilot study. Medication was titrated to a target dose of 4 mg QAM, 4 mg QPM, and 8 mg QHS by the end of week 2. Participants received 5 medical management treatment sessions. Participants were reminded 3 times each day via a text pager to take medications and to call a telephone monitoring system once daily to provide self‐reports of alcohol consumption and craving, the primary outcome measures. Results were analyzed using mixed linear regression adjusted for drinking days per week at baseline and week number. Results: Twenty of the 24 (83%) subjects completed. Among the completers, the prazosin group reported fewer drinking days per week than the placebo group during the final 3 weeks of the study. Since only 1 woman was randomized to placebo and only three women completed the trial, the following results focus on the 17 male completers. The prazosin group reported fewer drinking days per week and fewer drinks per week during the final 3 weeks of the study; average total number of drinking days for the placebo group 5.7 (SEM 1.9) versus 0.9 (SEM 0.5) for the prazosin group, and average total number of drinks 20.8 (SEM 6.5) for the placebo group versus 2.6 (SEM 1.3) for the prazosin group. Rates of adverse events were equivalent across conditions. Conclusions: Prazosin holds promise as a pharmacologic treatment for AD and deserves further evaluation in a larger controlled trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1530-0277.2008.00807.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 159

Metadata

Authors
Simpson, T. L., Saxon, A. J., Meredith, C. W., Malte, C. A., McBride, B., Ferguson, L. C., Gross, C. A., Hart, K. L., & Raskind, M.
Venue
Alcoholism: Clinical and Experimental Research
Publisher
Wiley
Published
2009-01-22
Volume
33
Issue
2
Pages
255-263
ISSN
  • 0145-6008 (ISSN-L)
  • 1530-0277
OpenAlex
W2136636160
Cited by
159
References
9
FWCI
6.99
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Pilot Trial of the Alpha‐1 Adrenergic Antagonist, Prazosin, for Alcohol Dependence. https://app.cochat.ai/papers/10.1111/j.1530-0277.2008.00807.x
The paper
Simpson, T. L., Saxon, A. J., Meredith, C. W., Malte, C. A., McBride, B., Ferguson, L. C., Gross, C. A., Hart, K. L., & Raskind, M. (2009). A Pilot Trial of the Alpha‐1 Adrenergic Antagonist, Prazosin, for Alcohol Dependence. Alcoholism: Clinical and Experimental Research. https://doi.org/10.1111/j.1530-0277.2008.00807.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.